Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice.
Animals
Cytokines
/ adverse effects
Dermatitis
/ immunology
Female
Humans
Imiquimod
/ adverse effects
Inflammation
/ metabolism
Intraepithelial Lymphocytes
/ metabolism
Keratinocytes
/ drug effects
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Psoriasis
/ chemically induced
Receptors, Interleukin-1
/ genetics
Skin
/ immunology
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
25
10
2019
revised:
12
02
2020
accepted:
13
02
2020
entrez:
23
2
2020
pubmed:
23
2
2020
medline:
29
5
2021
Statut:
epublish
Résumé
The IL-36 family cytokines have emerged as important mediators of dermal inflammation in psoriasis and have been reported to provide a proinflammatory stimulus to a variety of immune and stromal cell subsets in the inflamed skin. However, it remains to be determined which cell type, if any, in the skin plays a predominant role in mediating IL-36 cytokines instructive role in disease. Here, we demonstrate that targeted deletion of
Identifiants
pubmed: 32086318
pii: 3/4/e201900586
doi: 10.26508/lsa.201900586
pmc: PMC7035875
pii:
doi:
Substances chimiques
Cytokines
0
Receptors, Interleukin-1
0
interleukin-36 receptor, mouse
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 Hernández-Santana et al.
Références
Am J Hum Genet. 2011 Sep 9;89(3):432-7
pubmed: 21839423
J Immunol. 2011 Nov 15;187(10):5026-31
pubmed: 21984702
Clin Immunol. 2015 Mar;157(1):43-55
pubmed: 25572533
N Engl J Med. 2019 Mar 7;380(10):981-983
pubmed: 30855749
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8046-51
pubmed: 26080440
N Engl J Med. 2011 Aug 18;365(7):620-8
pubmed: 21848462
Mucosal Immunol. 2016 Sep;9(5):1193-204
pubmed: 26813344
Exp Dermatol. 2014 Oct;23(10):705-9
pubmed: 24815425
Eur J Immunol. 2015 Nov;45(11):2994-7
pubmed: 26389517
J Immunol. 2018 Jul 1;201(1):167-182
pubmed: 29794016
J Dermatol Sci. 2019 Sep;95(3):90-98
pubmed: 31362906
J Invest Dermatol. 2015 Dec;135(12):2992-3000
pubmed: 26203636
Immunity. 2011 Oct 28;35(4):596-610
pubmed: 21982596
J Exp Med. 2007 Oct 29;204(11):2603-14
pubmed: 17908936
MAbs. 2017 Oct;9(7):1143-1154
pubmed: 28726542
J Invest Dermatol. 2016 Nov;136(11):2251-2259
pubmed: 27388993
J Immunol. 2010 Oct 1;185(7):4354-62
pubmed: 20833839
J Vis Exp. 2017 Jul 14;(125):
pubmed: 28745643
J Clin Invest. 2012 Nov;122(11):3965-76
pubmed: 23064362
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284527
J Clin Invest. 2012 Jun;122(6):2252-6
pubmed: 22546855
Eur J Immunol. 2015 Nov;45(11):3022-33
pubmed: 26332438
Nat Commun. 2015 Jul 15;6:7687
pubmed: 26173479
Sci Rep. 2017 Nov 15;7(1):15631
pubmed: 29142248
J Vis Exp. 2016 Jan 10;(107):
pubmed: 26779653
J Leukoc Biol. 2015 Apr;97(4):645-52
pubmed: 25673295
Nat Commun. 2019 Sep 5;10(1):4003
pubmed: 31488830
Eur J Immunol. 2019 Sep;49(9):1306-1320
pubmed: 31250428
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5076-E5085
pubmed: 29760082
Ann N Y Acad Sci. 2018 Apr;1417(1):23-34
pubmed: 27783881
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):219-26
pubmed: 8990189
Biochem Biophys Res Commun. 2018 Nov 30;506(3):429-436
pubmed: 30352688
Development. 2000 Nov;127(22):4775-85
pubmed: 11044393
Curr Opin Pharmacol. 2012 Aug;12(4):486-90
pubmed: 22398321
J Invest Dermatol. 2011 Dec;131(12):2428-37
pubmed: 21881584
J Immunol. 2017 Nov 1;199(9):3129-3136
pubmed: 28972090
J Am Acad Dermatol. 2004 Nov;51(5):704-8
pubmed: 15523347
Sci Transl Med. 2017 Oct 11;9(411):
pubmed: 29021166